CNS Drugs

, Volume 29, Issue 8, pp 615–623 | Cite as

Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease

  • Celina S. Liu
  • Sarah A. Chau
  • Myuri Ruthirakuhan
  • Krista L. Lanctôt
  • Nathan HerrmannEmail author
Leading Article


Alzheimer’s disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness. The limited efficacy and high-risk profiles of current pharmacotherapies for the management of agitation and aggression in AD have driven the search for safer pharmacological alternatives. Over the past few years, there has been a growing interest in the therapeutic potential of medications that target the endocannabinoid system (ECS). The behavioural effects of ECS medications, as well as their ability to modulate neuroinflammation and oxidative stress, make targeting this system potentially relevant in AD. This article summarizes the literature to date supporting this rationale and evaluates clinical studies investigating cannabinoids for agitation and aggression in AD. Letters, case studies, and controlled trials from four electronic databases were included. While findings from six studies showed significant benefits from synthetic cannabinoids—dronabinol or nabilone—on agitation and aggression, definitive conclusions were limited by small sample sizes, short trial duration, and lack of placebo control in some of these studies. Given the relevance and findings to date, methodologically rigorous prospective clinical trials are recommended to determine the safety and efficacy of cannabinoids for the treatment of agitation and aggression in dementia and AD.


Nabilone Dronabinol Nocturnal Motor Activity Microglial Phagocytic Function Dronabinol Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards

Conflict of interest

Krista L. Lanctôt has received research grants from the Alzheimer Drug Discovery Fund, the Alzheimer Society of Canada, the National Institute of Health, AbbVie, Lundbeck, Pfizer, Sanofi-Aventis, Janssen-Ortho Inc., and Roche and Wyeth, and honoraria from AbbVie, Pfizer, Janssen-Ortho Inc., and MedImmune. Nathan Herrmann has received research grants from the Alzheimer Drug Discovery Fund, the Alzheimer Society of Canada, the National Institute of Health, Canadian Institute of Health Research, Lundbeck, and Roche, and consultant fees from Lundbeck, AbbVie, and Eli Lilly. Celina S. Liu, Sarah A. Chau, and Myuri Ruthirakuhan report no conflicts of interest.


This research was supported by the Alzheimer’s Drug Discovery Foundation (Grant 20140503) and the Alzheimer Society of Canada (Grant 15–17).


  1. 1.
    Wortmann M. Dementia: a global health priority—highlights from an ADI and World Health Organization report. Alzheimers Res Ther. 2012;4(5):40.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Garcia-Alberca JM, et al. Prevalence and comorbidity of neuropsychiatric symptoms in Alzheimer’s disease. Actas Esp Psiquiatr. 2008;36(5):265–70.PubMedGoogle Scholar
  3. 3.
    Lyketsos CG. Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments. Int Psychogeriatr. 2007;19(3):409–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Banerjee S, et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry. 2006;77(2):146–8.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci. 2007;62(8):908–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci. 1997;52(6):M369–77.PubMedCrossRefGoogle Scholar
  7. 7.
    Ballard CG, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Ballard C, et al. Management of agitation and aggression associated with Alzheimer’s disease: controversies and possible solutions. Curr Opin Psychiatry. 2009;22(6):532–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:Cd003476.PubMedGoogle Scholar
  10. 10.
    Schneider LS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.PubMedCrossRefGoogle Scholar
  11. 11.
    Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5((Suppl 1)):S5.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Bedse G, et al. The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease. J Alzheimers Dis. 2015;43(4):1115–36.PubMedGoogle Scholar
  13. 13.
    Rossi S, Motta C, Musella A, Centonze D. The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission. Neuropharmacology. 2015;96((Pt A)):105–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Sanchez AJ, Garcia-Merino A. Neuroprotective agents: cannabinoids. Clin Immunol. 2012;142(1):57–67.PubMedCrossRefGoogle Scholar
  15. 15.
    Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol. 2010;160(3):480–98.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77(2):299–318.PubMedCrossRefGoogle Scholar
  17. 17.
    Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;168:299–325.PubMedCrossRefGoogle Scholar
  18. 18.
    Kathmann M, Bauer U, Schlicker E. CB1 receptor density and CB1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventricularly administered antisense oligodeoxynucleotide. Naunyn Schmiedebergs Arch Pharmacol. 1999;360(4):421–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Karkkaine E, Tanila H, Laitinen JT. Functional autoradiography shows unaltered cannabinoid CB1 receptor signalling in hippocampus and cortex of APP/PS1 transgenic mice. CNS Neurol Disord Drug Targets. 2012;11(8):1038–44.PubMedCrossRefGoogle Scholar
  20. 20.
    Rapp PR, Heindel WC. Memory systems in normal and pathological aging. Curr Opin Neurol. 1994;7(4):294–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Mann DM. The pathogenesis and progression of the pathological changes of Alzheimer’s disease. Ann Med. 1989;21(2):133–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Moise AM, et al. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology. 2008;200(3):333–46.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Martin M, et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology. 2002;159(4):379–87.PubMedCrossRefGoogle Scholar
  24. 24.
    Klegeris A, Bissonnette CJ, McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol. 2003;139(4):775–86.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Sheng WS, et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia. 2005;49(2):211–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Tolon RM, et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009;1283:148–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Vilela FC, Giusti-Paiva A. Cannabinoid receptor agonist disrupts behavioral and neuroendocrine responses during lactation. Behav Brain Res. 2014;263:190–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Rodriguez-Arias M, et al. CB1 cannabinoid receptor-mediated aggressive behavior. Neuropharmacology. 2013;75:172–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Lanctot KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13(1):5–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Lanctot KL, et al. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry. 2004;49(7):439–53.PubMedGoogle Scholar
  31. 31.
    Tanaka Y, et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer’s disease. Ann Nucl Med. 2003;17(7):567–73.PubMedCrossRefGoogle Scholar
  32. 32.
    Pinto T, Lanctot KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer’s type. Ageing Res Rev. 2011;10(4):404–12.PubMedGoogle Scholar
  33. 33.
    Chami L, Checler F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer’s disease. Mol Neurodegener. 2012;7:52.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Aso E, et al. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. J Alzheimers Dis. 2013;35(4):847–58.PubMedGoogle Scholar
  35. 35.
    Esposito G, et al. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med (Berl). 2006;84(3):253–8.CrossRefGoogle Scholar
  36. 36.
    Volicer L, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12(9):913–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Walther S, et al. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol. 2011;31(2):256–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Mahlberg R, Walther S. Actigraphy in agitated patients with dementia. Monitoring treatment outcomes. Z Gerontol Geriatr. 2007;40(3):178–84.PubMedCrossRefGoogle Scholar
  39. 39.
    Walther S, et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006;185(4):524–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Woodward MR, et al. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry. 2014;22(4):415–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry. 2008;23(1):116–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Cheer JF, et al. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci. 2004;24(18):4393–400.PubMedCrossRefGoogle Scholar
  43. 43.
    Pistis M, et al. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry. 2004;56(2):86–94.PubMedCrossRefGoogle Scholar
  44. 44.
    Kirilly E, Hunyady L, Bagdy G. Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists. J Neural Transm. 2013;120(1):177–86.PubMedCrossRefGoogle Scholar
  45. 45.
    Haj-Dahmane S, Shen RY. Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology. 2011;61(3):414–20.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Best AR, Regehr WG. Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J Neurosci. 2008;28(25):6508–15.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Sigel E, et al. The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci USA. 2011;108(44):18150–5.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Spivak CE, Lupica CR, Oz M. The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol. 2007;72(4):1024–32.PubMedCrossRefGoogle Scholar
  49. 49.
    Uriguen L, et al. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology. 2004;46(7):966–73.PubMedCrossRefGoogle Scholar
  50. 50.
    Steiner MA, et al. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J. 2008;8(3):196–208.PubMedCrossRefGoogle Scholar
  51. 51.
    Aso E, et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem. 2008;105(2):565–72.PubMedCrossRefGoogle Scholar
  52. 52.
    Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav. 2003;43(1):60–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Arborelius L, et al. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160(1):1–12.PubMedCrossRefGoogle Scholar
  54. 54.
    Gregus A, et al. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav Brain Res. 2005;156(1):105–14.PubMedCrossRefGoogle Scholar
  55. 55.
    Vermeiren Y, et al. Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis. 2014;41(3):819–33.PubMedGoogle Scholar
  56. 56.
    Casarejos MJ, et al. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis. 2013;35(3):525–39.PubMedGoogle Scholar
  57. 57.
    Palmer AM, et al. Presynaptic serotonergic dysfunction in patients with Alzheimer’s disease. J Neurochem. 1987;48(1):8–15.PubMedCrossRefGoogle Scholar
  58. 58.
    Procter AW, et al. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochem Res. 1992;17(9):917–22.PubMedCrossRefGoogle Scholar
  59. 59.
    Lai MK, et al. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003;974(1–2):82–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Lanctot KL, et al. Central serotonergic activity is related to the aggressive behaviors of Alzheimer’s disease. Neuropsychopharmacology. 2002;27(4):646–54.PubMedGoogle Scholar
  61. 61.
    Mintzer J, et al. Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer’s dementia and agitation. Biol Psychiatry. 1998;44(9):918–21.PubMedCrossRefGoogle Scholar
  62. 62.
    Haring M, et al. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience. 2007;146(3):1212–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Egertova M, Cravatt BF, Elphick MR. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience. 2003;119(2):481–96.PubMedCrossRefGoogle Scholar
  64. 64.
    Alexander G, et al. Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer’s disease. Behav Brain Res. 2011;216(1):77–83.PubMedCrossRefGoogle Scholar
  65. 65.
    Pugh PL, et al. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer’s disease. Behav Brain Res. 2007;178(1):18–28.PubMedCrossRefGoogle Scholar
  66. 66.
    Ramakers IH, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med. 2013;43(5):911–20.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Wu J, et al. Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol Aging. 2013;34(3):791–804.PubMedCrossRefGoogle Scholar
  68. 68.
    Martin-Moreno AM, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflamm. 2012;9:8.CrossRefGoogle Scholar
  69. 69.
    Guadagna S, et al. Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia. Neurobiol Aging. 2012;33(12):2798–806.PubMedCrossRefGoogle Scholar
  70. 70.
    Holmes C, Butchart J. Systemic inflammation and Alzheimer’s disease. Biochem Soc Trans. 2011;39(4):898–901.PubMedCrossRefGoogle Scholar
  71. 71.
    Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer’s disease: molecular mechanisms. Int J Dev Neurosci. 2006;24(2–3):167–76.PubMedCrossRefGoogle Scholar
  72. 72.
    Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia. 2000;29(1):58–69.PubMedCrossRefGoogle Scholar
  73. 73.
    Facchinetti F, et al. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia. 2003;41(2):161–8.PubMedCrossRefGoogle Scholar
  74. 74.
    van der Stelt M, et al. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci. 2006;63(12):1410–24.PubMedCrossRefGoogle Scholar
  75. 75.
    Farkas S, et al. [(1)(2)(5)I]SD-7015 reveals fine modalities of CB(1) cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer’s disease. Neurochem Int. 2012;60(3):286–91.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal. 2014;6(1–2):24–30.PubMedCrossRefGoogle Scholar
  77. 77.
    Zogopoulos P, et al. The role of endocannabinoids in pain modulation. Fundam Clin Pharmacol. 2013;27(1):64–80.PubMedCrossRefGoogle Scholar
  78. 78.
    Wiley JL, et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol. 2005;145(3):293–300.PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Whyte LS, et al. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol. 2012;165(8):2584–97.PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Burston JJ, Woodhams SG. Endocannabinoid system and pain: an introduction. Proc Nutr Soc. 2014;73(1):106–17.PubMedCrossRefGoogle Scholar
  81. 81.
    Ballard C, Corbett A. Agitation and aggression in people with Alzheimer’s disease. Curr Opin Psychiatry. 2013;26(3):252–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Husebo BS, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065.PubMedCentralPubMedCrossRefGoogle Scholar
  83. 83.
    Bestard JA, Toth CC. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2011;11(4):353–68.PubMedCrossRefGoogle Scholar
  84. 84.
    Skrabek RQ, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164–73.PubMedCrossRefGoogle Scholar
  85. 85.
    Wissel J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol. 2006;253(10):1337–41.PubMedCrossRefGoogle Scholar
  86. 86.
    Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci. 2011;5:60.PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal. 2011;3(7–8):466–78.PubMedCrossRefGoogle Scholar
  88. 88.
    Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett. 2010;197(3):157–62.PubMedCrossRefGoogle Scholar
  89. 89.
    Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735–44.PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    CADTH Rapid Response Reports, in Nabilone for non-chemotherapy associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines. 2014, Canadian Agency for Drugs and Technologies in Health Copyright (c). Ottawa: 2014 Canadian Agency for Drugs and Technologies in Health.Google Scholar
  91. 91.
    Lemberger L, Rowe H. Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther. 1975;18(06):720–6.PubMedGoogle Scholar
  92. 92.
    Whiting PF, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73.PubMedCrossRefGoogle Scholar
  93. 93.
    Smith PH, et al. Marijuana withdrawal and aggression among a representative sample of US marijuana users. Drug Alcohol Depend. 2013;132(1–2):63–8.PubMedCentralPubMedCrossRefGoogle Scholar
  94. 94.
    Budney AJ, et al. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry. 2001;58(10):917–24.PubMedCrossRefGoogle Scholar
  95. 95.
    Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153(2):319–34.PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    Han S, et al. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J Med Chem. 2013;56(21):8224–56.PubMedCrossRefGoogle Scholar
  97. 97.
    Lee JH, et al. Intact cannabinoid CB1 receptors in the Alzheimer’s disease cortex. Neurochem Int. 2010;57(8):985–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Celina S. Liu
    • 1
    • 2
  • Sarah A. Chau
    • 1
    • 2
  • Myuri Ruthirakuhan
    • 2
  • Krista L. Lanctôt
    • 1
    • 2
    • 3
  • Nathan Herrmann
    • 2
    • 3
    Email author
  1. 1.Department of Pharmacology and ToxicologyUniversity of TorontoTorontoCanada
  2. 2.Neuropsychopharmacology Research GroupHurvitz Brain Sciences Program Sunnybrook Research Institute, Sunnybrook Health Sciences CentreTorontoCanada
  3. 3.Department of PsychiatryUniversity of TorontoTorontoCanada

Personalised recommendations